S3 Table presents the distribution of patients stratified by the ypT and ypN statuses. The results illustrated that 6.6% of patients were categorized as ypT3 or ypT4, and 41.1% of patients had a ypN-positive status. Regarding the tumor response to NAE, 50 of 107 (46.7%) patients exhibited significant responses (grades 1b–3, JBCS criteria). The histological tumor responses of all patients were as follows: grade 3 (pCR), 1 patient (0.9%); grade 2b, 1 patient (0.9%); grade 2a, 8 patients (7.5%); grade 1b, 40 patients (37.4%); and grade 0–1a, 57 patients (53.3%; S3 Table). The gene discussed is RAB11B; the disease is neoplasm.